

**Sun Pharmaceutical Industries Limited**  
Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



**FOR IMMEDIATE RELEASE**

**Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management**

Company to launch product after the expiry of semaglutide patent in India

**Mumbai, India, January 23, 2026:** Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity.

Sun Pharma will launch generic semaglutide injection under the brand name, Noveltreat, after the expiry of semaglutide patent in India. The product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly. The product is administered via an easy-to-use prefilled pen, designed to support convenient and accurate dosing.

“Obesity and diabetes have emerged as two of the most pressing health challenges confronting India and GLP-1 based therapies can play a meaningful role in addressing this growing burden. Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management. As India’s largest pharmaceutical company with leadership in cardiometabolic therapies, we are committed to improving access to generic semaglutide across the country after the patent expiry”, said Kirti Ganorkar, Managing Director, Sun Pharma.

“GLP-1 receptor agonists like semaglutide are an important scientific advancement for overall metabolic health, not just weight. These treatments should be combined with appropriate lifestyle measures such as diet and physical activity. They should be taken under close medical supervision. We are seeing growing patient interest in this therapy, and improved accessibility will help address unmet needs”, said Dr. Unnikrishnan A G, Chief Endocrinologist and CEO, Chellaram Diabetes Institute.

In December 2025, Sun Pharma received DCGI approval for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name Sematrinity, after the expiry of semaglutide patent in India.

**Sun Pharmaceutical Industries Limited**  
Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



## About GLP-1 class of drugs

GLP-1 agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity.<sup>i</sup> These therapies including semaglutide, are considered as highly effective treatment options for people with T2DM and obesity, while reducing cardiovascular and renal morbidity and mortality.<sup>ii</sup>

## Obesity and diabetes

As per National Family Health Survey-5 (NFHS-5), almost one in four Indians between the age group 15-49 is now overweight or obese.<sup>iii</sup> Obesity is associated with several comorbidities, including, but not limited to, metabolic and cardiovascular consequences, and increased risk of cancer, morbidity and mortality.<sup>iv</sup> There is an urgent need to mandate timely screening, timely treatment with effective therapies and lifestyle interventions, and maintaining weight loss in these patients to ensure enhanced treatment outcomes.<sup>iii</sup>

As per the ICMR INDIAB 17 study published in 2023 an estimated 101.3 million people had diabetes in India.<sup>v</sup> Diabetic patients are at risk of complications such as blindness, kidney failure, amputations, and heart attacks.<sup>vi</sup> About 64% of patients in India do not reach their HbA1c targets.<sup>vii</sup> Therefore, there is need for a comprehensive approach towards managing diabetes, including newer and more efficacious therapies.

## **About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)**

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on [LinkedIn](#) & [X](#) (Formerly Twitter).

<sup>i</sup> Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK551568/>

<sup>ii</sup> Drucker, D.J. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov 24, 631–650 (2025). <https://doi.org/10.1038/s41573-025-01183-8>

<sup>iii</sup> Kalra S, et al. Defining and Diagnosing Obesity in India: A Call for Advocacy and Action. J Obes. 2023: 4178121. doi: 10.1155/2023/4178121. PMID: 38026823; PMCID: PMC10645500

<sup>iv</sup> Ray, S, et al. An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update. Expert Review of Clinical Pharmacology, 2024; 17(4), 349–362. <https://doi.org/10.1080/17512433.2024.2330468>

<sup>v</sup> ICMR-INDIAB-17. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489

<sup>vi</sup> Mohan V, Tiwaskar M. The Unrelenting Epidemic of Diabetes in India: Do the Numbers Matter? J Assoc Physicians India 2025;73(5):12-13

**Sun Pharmaceutical Industries Limited**  
Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



---

<sup>vii</sup> Anjana RM et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study. Lancet Diabetes Endocrinol. 2022 Jun;10(6):430-441

### **Contacts: Sun Pharma**

#### **Investors**

Dr. Abhishek Sharma  
Tel +91 22 4324 4324, Xtn 2929  
Tel (D) +91 22 4324 2929  
Mobile +91 98196 86016  
E mail abhi.sharma@sunpharma.com

#### **Media**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel (D) +91 22 4324 5373  
Mobile +91 98104 71414  
E mail gaurav.chugh@sunpharma.com